Skip to content

Efficacy and safety of temporal interference stimulation (TIS) in patients with prolonged disorders of consciousness (pDoC)

Efficacy and safety of temporal interference stimulation (TIS) in patients with prolonged disorders of consciousness (pDoC)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121642
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prolonged disorders of consciousness (pDoC)

Interventions

Experimental group:2-week TIS stimulation (20 minutes/time, 2 times/day, 5 days/week, a total of 10 times) combined with conventional rehabilitation therapy

Sponsors

West China hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to the Expert Consensus on Naming and Classification of Chronic Mental Disorders [13], it meets the diagnostic criteria of VS/UWS or MCS; 2. Acquired brain injury (such as traumatic brain injury, stroke, hypoxic-ischemic encephalopathy, etc.), and within 4 weeks to 12 months of the onset of consciousness disorders; 3. Vital signs and clinical conditions remain stable for at least one week; 4. Age between 18-70 years old; 5. Sign the informed consent form by the legal representative; 6. Prior to enrollment, an MRI examination can be performed to accurately locate the lesion site.

Exclusion criteria

Exclusion criteria: 1. Contraindications for TIS (such as implantation of pacemakers, metal brain implants, or drug-resistant epilepsy); 2. Serious uncontrolled systemic diseases (such as severe heart failure, liver and kidney failure, etc.); 3. Untreated intracranial aneurysms, severe hydrocephalus or extensive brain softening lesions, and active intracranial hypertension; 4. Skull defects in the dorsolateral prefrontal or parietal regions, making it impossible to place electrodes for localization; 5. Use sedatives, sodium calcium channel blockers (such as carbamazepine), or N-methyl-D-aspartate receptor antagonists (such as dexmedetomidine) that may significantly affect consciousness levels or brain excitability; 6. Previous presence of neurodegenerative diseases; 7. Unable to tolerate fMRI, EEG, fNIRS, TMS-EEG, ERP and other examinations, or have contraindications for related examinations; 8. Currently participating in other interventional clinical trials that may interfere with the results of this study.

Design outcomes

Primary

MeasureTime frame
safety;

Secondary

MeasureTime frame
Coma Recovery Scale-Revised, CRS-R;Glasgow Coma Scale, GCS;electroencephalography, EEG;Resting-state Functional Magnetic Resonance Imaging,rest-fMRI;functional near - infrared spectroscopy,?fNIRS;transcranial magnetic stimulation - electroencephalography, TMS-EEG;event-related brain potential, ERP;

Countries

China

Contacts

Public ContactCheng Huang

West China Hospital, Sichuan University

chenghuang_scu@163.com+86 189 8060 3143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026